ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering a comprehensive approach to the hepatocellular carcinoma (HCC) patient's assessment, the aim of the study was to identify the clinical significance of selected indices as prognostic factors in HCC patients treated with sorafenib in daily clinical practice. Materials and methods: Out of 122 available HCC patients, 72 treated with sorafenib (800 mg per day) had their data analyzed. To assess nutritional status, liver condition and tumor burden, changes in the following indices were analyzed: body mass index (BMI), international normalized ratio (INR), the systemic inflammatory response index (SIRI), the platelet-to-lymphocyte ratio (PLR), the neutrophil-to-lymphocyte ratio (NLR), the model for end-stage liver disease (MELD), the albumin-bilirubin (ALBI), the prognostic nutritional index (PNI). Survival analyses were performed. Results: Significant differences were observed during treatment in body mass, BMI, monocyte, albumin, aspartate aminotransferase, bilirubin, SIRI, PNI and ALBI. Survival analyses revealed significant differences in progression-free survival (PFS) in median survival for: SIRI, NLR, ALBI, PNI and albumin (p < 0.001). For overall survival (OS), survival analyses revealed significant differences for albumin and PNI (p < 0.05). Cox regression for PFS and OS, adjusted for age, sex and BMI, revealed significant hazard ratios for albumin and for SIRI in PFS only. Conclusions: Albumin remains an important prognostic factor for both PFS and OS in HCC patients; however, new indices can be successfully used in clinical practice as valuable prognostic tools for PFS in patients with HCC treated with sorafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.